Should psychiatrists be more cautious about the use of antipsychotics for patients with borderline personality disorder?
- PMID: 35728973
- PMCID: PMC9561842
- DOI: 10.47626/1516-4446-2022-2574
Should psychiatrists be more cautious about the use of antipsychotics for patients with borderline personality disorder?
Conflict of interest statement
JCS has received grants from Alkermes and Allergan; and has been a consultant for Asofarma, Atai, Boehringer, Compass, Johnson and Johnson, Livanova, Pfizer, Relmada, Sanofi, and Sunovian. RFD declares no conflicts of interest.
References
-
- Murray RM, Quattrone D, Natesan S, van Os J, Nordentoft M, Howes O, et al. Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? Br J Psychiatry. 2016;209:361–5. - PubMed
-
- Gunderson JG, Herpertz SC, Skodol AE, Torgersen S, Zanarini MC. Borderline personality disorder. Nat Rev Dis Primers. 2018;4:18029. - PubMed
-
- Paton C, Crawford MJ, Bhatti SF, Patel MX, Barnes TR. The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK mental health services. J Clin Psychiatry. 2015;76:e512–8. - PubMed
-
- Pascual JC, Martín-Blanco A, Soler J, Ferrer A, Tiana T, Alvarez E, et al. A naturalistic study of changes in pharmacological prescription for borderline personality disorder in clinical practice: from APA to NICE guidelines. Int Clin Psychopharmacol. 2010;25:349–55. - PubMed
-
- Zanarini MC, Frankenburg FR, Hennen J, Silk KR. Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years. J Clin Psychiatry. 2004;65:28–36. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources